Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Illegal cannabis use is common among Danes with multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Multiple Sclerosis Care Unit

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Xavier Montalban
  • Ralf Gold
  • Alan J Thompson
  • Susana Otero-Romero
  • Maria Pia Amato
  • Dhia Chandraratna
  • Michel Clanet
  • Giancarlo Comi
  • Tobias Derfuss
  • Franz Fazekas
  • Hans Peter Hartung
  • Eva Havrdova
  • Bernhard Hemmer
  • Ludwig Kappos
  • Roland Liblau
  • Catherine Lubetzki
  • Elena Marcus
  • David H Miller
  • Tomas Olsson
  • Steve Pilling
  • Krysztof Selmaj
  • Axel Siva
  • Per Soelberg Sorensen
  • Maria Pia Sormani
  • Christoph Thalheim
  • Heinz Wiendl
  • Frauke Zipp
Vis graf over relationer

BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.

OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.

METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.

RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.

CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.

OriginalsprogEngelsk
TidsskriftMultiple sclerosis (Houndmills, Basingstoke, England)
Vol/bind24
Udgave nummer2
Sider (fra-til)96-120
Antal sider25
ISSN1352-4585
DOI
StatusUdgivet - feb. 2018

ID: 56323987